Assembly Biosciences (ASMB) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Assembly Biosciences (ASMB) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 3.8% versus a loss of 57.8%. Over five years, ASMB leads with a -41.3% price change compared with -55.8% for SPRY. Assembly Biosciences is the larger company by market cap ($467.3 million vs $433.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | SPRY |
|---|---|---|
| Share price | $22.95 | $4.36 |
| Market cap | $467.28M | $433.59M |
| 1-day change | +3.47% | +1.51% |
| YTD return | -32.52% | -62.58% |
| 1-year return | -3.81% | -57.79% |
| 5-year return | -41.33% | -55.78% |
| P/E ratio (TTM) | 21.25 | — |
| EPS (TTM) | $1.08 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $13.15 |
| 52-week low | $21.80 | $3.99 |
| Distance from 52-week high | -42.21% | -66.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +126.58% | +416.06% |
| Average volume | 277.22K | 1.86M |
| Shares outstanding | 20.36M | 99.45M |
| Employees | 73 | 195 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASMB has outperformed SPRY by 54.0 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Healthcare · Biotechnology · 73 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Healthcare · Biotechnology · 195 employees
ASMB vs SPRY FAQ
Which is bigger, Assembly Biosciences or ARS Pharmaceuticals?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $467.28M compared with $433.59M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, ASMB or SPRY?
ASMB returned -3.81% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.